Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche's Emicizumab Progresses Against Hemophilia's Next Big Challenge: Patients With Factor VIII Inhibitors

Executive Summary

Interim results from the first patients enrolled in the Phase III HAVEN 2 study suggest Roche’s potential anti-hemophilia monoclonal antibody emicizumab reduces bleeds over time in younger as well as in older patients with inhibitors to factor VIII.

You may also be interested in...



Seven Clinical Trial Read-Outs Due In Q4

The last three months of the year should see data reporting from a number of key studies for novel products including Roche's emicizumab. Scrip takes a look at some of the more interesting studies expected by year end, with the help of analysts from Informa's Biomedtracker.

Momentum Builds For Tomorrow's More Convenient Hemophilia Drugs

Updates for a range of new therapies from Roche, Alnylam, BioMarin and Spark Therapeutics at the ISTH meeting in Berlin show progress in development of new hemophilia alternatives, with more late-stage programs kicking off.

Phase III Updates Bode Well For Filings Of Roche's Emicizumab In Hemophilia

Roche believes it can address thrombotic safety issues that cropped up with bispecific antibody emicizumab by providing regulators with guidance on dosing.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC027449

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel